Bullish Or Bearish For Evaxion Biotech A/S ADR (NASDAQ: EVAX) In 2025

Evaxion Biotech A/S ADR (NASDAQ:EVAX) shares, rose in value on Thursday, April 16, with the stock price down by -0.08% to the previous day’s close as strong demand from buyers drove the stock to $1.31.

Actively observing the price movement in the last trading, the stock closed the session at $1.31, falling within a range of $1.25 and $1.315. The value of beta (5-year monthly) was -0.247. Referring to stock’s 52-week performance, its high was $22.05, and the low was $1.20. On the whole, EVAX has fluctuated by -29.62% over the past month.

With the market capitalization of Evaxion Biotech A/S ADR currently standing at about $1.83 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-31.

Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that EVAX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the price of EVAX currently trading nearly -16.67% and -32.68% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 29.55, while the 7-day volatility ratio is showing 6.78% which for the 30-day chart, stands at 8.50%. Furthermore, Evaxion Biotech A/S ADR (EVAX)’s beta value is -0.10, and its average true range (ATR) is 0.16.

A comparison of Evaxion Biotech A/S ADR (EVAX) with its peers suggests the former has fared considerably weaker in the market. EVAX showed an intraday change of -0.08% in last session, and over the past year, it shrunk by -93.52%%.

Data on historical trading for Evaxion Biotech A/S ADR (NASDAQ:EVAX) indicates that the trading volumes over the past 10 days have averaged 80860.0 and over the past 3 months, they’ve averaged 2.31 million. According to company’s latest data on outstanding shares, there are 1.40 million shares outstanding.

Nearly 9.24% of Evaxion Biotech A/S ADR’s shares belong to company insiders and institutional investors own 4.27% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 41825.0 shares as on 2025-03-31, resulting in a short ratio of 0.55. According to the data, the short interest in Evaxion Biotech A/S ADR (EVAX) stood at 88.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 86685.0. The stock has fallen by -69.03% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the EVAX stock heading into the next quarter.

Most Popular